Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2024

Revenue Recognition

Schedule of disaggregation of revenues by payer types

	Three months ended				Nine months ended
	September 30,				September 30,
	2024		2023		2024		2023
	(in thousands)
Insurance carriers	$	405,208	$	239,780	$	1,130,364	$	676,680
Laboratory and other partners		27,622		21,731		70,152		71,985
Patients		6,928		6,795		20,334		22,801
Total revenues	$	439,758	$	268,306	$	1,220,850	$	771,466

Schedule of total revenue by geographic area

	Three months ended				Nine months ended
	September 30,				September 30,
	2024		2023		2024		2023
	(in thousands)
United States	$	426,274	$	259,870	$	1,190,559	$	746,420
Americas, excluding U.S.		2,002		1,288		5,084		3,652
Europe, Middle East, India, Africa		7,722		5,255		18,339		16,071
Asia Pacific and Other		3,760		1,893		6,868		5,323
Total revenues	$	439,758	$	268,306	$	1,220,850	$	771,466

Schedule of beginning and ending balances of accounts receivable and deferred revenues

	Balance at
	September 30,		December 31,
	2024		2023
	(in thousands)
Assets:
Accounts receivable, net	$	306,876	$	278,289
Liabilities:
Deferred revenue, current portion	$	17,886	$	16,612
Deferred revenue, long-term portion (1)		16,916		19,128
Total deferred revenues	$	34,802	$	35,740

Schedule of changes in the balance of deferred revenues

	Balance at
	September 30,
	2024			2023
	(in thousands)
Beginning balance	$	35,740	$	30,778
Increase in deferred revenues		23,968		24,553
Revenue recognized during the period that was included in deferred revenues at the beginning of the period		(12,102)		(9,610)
Revenue recognized from performance obligations satisfied within the same period		(12,804)		(9,676)
Ending balance	$	34,802	$	36,045